Hologic, Inc. (NASDAQ:HOLX) has been given an average recommendation of “Buy” by the sixteen ratings firms that are presently covering the company, MarketBeat Ratings reports. One research analyst has rated the stock with a sell recommendation, five have issued a hold recommendation, nine have given a buy recommendation and one has assigned a strong buy recommendation to the company. The average 1 year target price among analysts that have issued ratings on the stock in the last year is $48.36.
A number of equities analysts recently weighed in on HOLX shares. Goldman Sachs Group upgraded shares of Hologic from a “buy” rating to a “conviction-buy” rating and lifted their price objective for the company from $45.00 to $50.00 in a research report on Friday, December 8th. Cowen upgraded shares of Hologic from a “market perform” rating to an “outperform” rating and set a $51.00 price objective on the stock in a research report on Monday, December 11th. Needham & Company LLC reiterated a “buy” rating and issued a $50.00 price objective on shares of Hologic in a research report on Thursday, February 1st. Bank of America upgraded shares of Hologic from a “neutral” rating to a “buy” rating and set a $50.00 price objective on the stock in a research report on Thursday, January 4th. Finally, BidaskClub lowered shares of Hologic from a “hold” rating to a “sell” rating in a research report on Saturday, January 13th.
Hologic (HOLX) traded up $0.91 during trading hours on Wednesday, reaching $39.57. 1,608,470 shares of the company were exchanged, compared to its average volume of 2,549,784. Hologic has a 1 year low of $35.33 and a 1 year high of $46.80. The company has a current ratio of 1.25, a quick ratio of 0.98 and a debt-to-equity ratio of 0.87. The stock has a market cap of $10,690.61, a price-to-earnings ratio of 10.44, a price-to-earnings-growth ratio of 1.74 and a beta of 0.84.
In other Hologic news, Director Namal Nawana bought 6,600 shares of Hologic stock in a transaction on Tuesday, February 13th. The stock was bought at an average price of $37.88 per share, with a total value of $250,008.00. Following the completion of the acquisition, the director now owns 6,954 shares in the company, valued at $263,417.52. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 0.79% of the stock is currently owned by company insiders.
A number of institutional investors have recently added to or reduced their stakes in HOLX. Crossmark Global Holdings Inc. acquired a new stake in Hologic in the third quarter valued at $1,262,000. State Board of Administration of Florida Retirement System grew its holdings in Hologic by 0.3% in the 3rd quarter. State Board of Administration of Florida Retirement System now owns 406,630 shares of the medical equipment provider’s stock valued at $14,919,000 after buying an additional 1,351 shares during the period. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. grew its holdings in Hologic by 7.6% in the 3rd quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. now owns 43,323 shares of the medical equipment provider’s stock valued at $1,590,000 after buying an additional 3,048 shares during the period. Stevens Capital Management LP purchased a new stake in Hologic in the 3rd quarter valued at about $5,501,000. Finally, State of Wisconsin Investment Board grew its holdings in Hologic by 77.6% in the 3rd quarter. State of Wisconsin Investment Board now owns 442,751 shares of the medical equipment provider’s stock valued at $16,245,000 after buying an additional 193,484 shares during the period. 96.95% of the stock is owned by institutional investors.
WARNING: This report was reported by Ticker Report and is the sole property of of Ticker Report. If you are viewing this report on another domain, it was illegally copied and reposted in violation of US & international trademark & copyright legislation. The legal version of this report can be accessed at https://www.tickerreport.com/banking-finance/3253683/hologic-inc-holx-receives-48-36-average-pt-from-analysts.html.
Hologic Company Profile
Hologic, Inc is a developer, manufacturer and supplier of diagnostics products, medical imaging systems and surgical products with an emphasis on women’s health. The Company operates through four segments: Diagnostics, Breast Health, GYN Surgical and Skeletal Health. The diagnostics products include Aptima family of assays, ThinPrep system, the Rapid Fetal Fibronectin Test and Procleix blood screening assays.
Receive News & Ratings for Hologic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hologic and related companies with MarketBeat.com's FREE daily email newsletter.